Valitor

About

Valitor, Inc. is a biotechnology company based in Berkeley, California, founded in 2010. The company specializes in developing advanced, protein-based drugs using its proprietary multivalent biopolymer technology. Valitor focuses on creating a new generation of ophthalmic medicines by modifying therapeutic proteins to enhance their pharmacokinetics, target specificity, and bioactivity. The core of Valitor's innovation is its Multivalent Polymer (MVP) technology platform, which allows for the assembly of novel macromolecular entities. This platform provides independent control over various drug attributes, such as extended target tissue retention, protection from deactivation, and high potency engineering. Valitor's lead product is in development for treating wet age-related macular degeneration (AMD), with promising data presented at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting. The company also has development pipelines for oncology and orthopedics products. Valitor operates with a small team of fewer than 25 employees and aims to improve patient quality of life while reducing healthcare costs.